- Dossier preparation manuals
- Q&A
- Create support request
- IUCLID user community
- Additional information
- Video tutorials

SuperUser EPA/ORD/CCTE/SCDCD

- User Settings
- Logout

- Dashboard
- Substances
- Octane, 1,1,1,2,2,3,3,4,4,5,5,6,6-t...

Filtered aggr_1

9b1825b9-a6f9-44a4-b59c-737c0335487b

View Dossiers | Validate

- Export to i6z
- Extract to dataset
- Create component PDF/RTF
- Create document PDF/RTF
- Compare
- Generate report
- Dissemination preview

Type at least 3 characters

REACH Complete
Octane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-

UUID 4ccef3b2-b123-4ef4-9c8e-c6cced1935d3 Hide empty fields

- Compare Document

0 1 0

Administrative data | Data source | Materials and methods | Results and discussion | Overall remarks, attachments | Applicant's summary and conclusion

Administrative data

Endpoint
short-term repeated dose toxicity: oral

Type of information
experimental study

Adequacy of study

key study

☐ Robust study summary

☐ Used for classification

☐ Used for SDS

Study period

Reliability
1 (reliable without restriction)

Rationale for reliability incl. deficiencies

Data waiving

Justification for data waiving

Justification for type of information

Attached justification

Attached justification Reason / purpose Actions

Cross-reference

Reason / purpose for cross-reference Related information Remarks Actions

Data source

Reference

- study report | Unnamed | 2007 | 2007-03-21

Data access

Data protection claimed

Materials and methods

Test guideline

Qualifier Guideline Version / remarks Deviations Actions 1
Qualifier
according to guideline
Guideline
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
Version / remarks
Deviations
2
Qualifier
according to guideline
Guideline
EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
Version / remarks
Deviations

Principles of method if other than guideline

GLP compliance
yes

Limit test
no

Test material

Test material information

- Unnamed | Unnamed | 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorooctane | EC 700-684-7 | 80793-17-5

Additional test material information

Specific details on test material used for the study

Specific details on test material used for the study (confidential)

Test animals

Species
rat

Strain
other:

Details on species / strain selection

Sex
male/female

Details on test animals or test system and environmental conditions

Administration / exposure

Route of administration
oral: gavage

Details on route of administration

Vehicle

Details on oral exposure

Analytical verification of doses or concentrations

Details on analytical verification of doses or concentrations

Duration of treatment / exposure
28 days

Frequency of treatment

Doses / concentrations

Dose / conc. Remarks Actions

No. of animals per sex per dose

Control animals

Details on study design

Positive control

Examinations

Observations and examinations performed and frequency

Sacrifice and pathology

Optional endpoint(s)

Other examinations

Statistics

Any other information on materials and methods incl. tables

Results and discussion

Results of examinations

Clinical signs

Description (incidence and severity)

Mortality

Description (incidence)

Body weight and weight changes

Description (incidence and severity)

Food consumption and compound intake (if feeding study)

Description (incidence and severity)

Food efficiency

Description (incidence and severity)

Water consumption and compound intake (if drinking water study)

Description (incidence and severity)

Ophthalmological findings

Description (incidence and severity)

Haematological findings

Description (incidence and severity)

Clinical biochemistry findings

Description (incidence and severity)

Endocrine findings

Description (incidence and severity)

Urinalysis findings

Description (incidence and severity)

Behaviour (functional findings)

Description (incidence and severity)

Immunological findings

Description (incidence and severity)

Organ weight findings including organ / body weight ratios

Description (incidence and severity)

Gross pathological findings

Description (incidence and severity)

Neuropathological findings

Description (incidence and severity)

Histopathological findings: non-neoplastic

Description (incidence and severity)

Histopathological findings: neoplastic

Description (incidence and severity)

Other effects

Description (incidence and severity)

Details on results

Effect levels

Key result Dose descriptor Effect level Based on Sex Basis for effect level Remarks on result Actions 1

☐ Key result
Dose descriptor
NOAEL
Effect level
40 mg/kg bw/day (actual dose received)
Based on
test mat.
Sex
male/female
Basis for effect level

- other:

Remarks on result

Target system / organ toxicity

Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions 1

☐ Key result
Critical effects observed
not specified
Lowest effective dose / conc.
System
hepatobiliary
Organ

- liver

Treatment related

Dose response relationship
Relevant for humans

Any other information on results incl. tables

Overall remarks, attachments

Overall remarks

Attachments

Type Attached (confidential) document Attached (sanitised) documents for publication Remarks Actions

---

Illustration (picture/graph)

Applicant's summary and conclusion

Conclusions

Executive summary

TOP

- Dashboard
- Substances
- Mixtures / Products
- Articles
- Categories

Toolbox

- Template
- Manage Reports

Inventory manager

- Contact
- Legal entity
- Sites
- Reference substance
- Test material
- Literature reference

User management

- User Settings
- Users
- Roles

About IUCLID

- About
- Help